• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

EBioMedicine . SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals

tetano

Editor, Senior Moderator
EBioMedicine


. 2022 Feb 19;77:103888.
doi: 10.1016/j.ebiom.2022.103888. Online ahead of print.
SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals


Alessandra Ruggiero[SUP] 1 [/SUP], Chiara Piubelli[SUP] 2 [/SUP], Lucia Calciano[SUP] 3 [/SUP], Simone Accordini[SUP] 3 [/SUP], Maria Teresa Valenti[SUP] 4 [/SUP], Luca Dalle Carbonare[SUP] 4 [/SUP], Gabriel Siracusano[SUP] 5 [/SUP], Nigel Temperton[SUP] 6 [/SUP], Natalia Tiberti[SUP] 2 [/SUP], Silvia Stefania Longoni[SUP] 2 [/SUP], Massimo Pizzato[SUP] 7 [/SUP], Silvia Accordini[SUP] 7 [/SUP], A.M.S.L.V. group; Tobia Fantoni[SUP] 1 [/SUP], Lucia Lopalco[SUP] 5 [/SUP], Alberto Beretta[SUP] 8 [/SUP], Zeno Bisoffi[SUP] 9 [/SUP], Donato Zipeto[SUP] 10 [/SUP]



Affiliations

Abstract

Background: Currently, evaluation of the IgG antibodies specific for the SARS-CoV-2 Spike protein following vaccination is used worldwide to estimate vaccine response. Limited data are available on vaccine-elicited IgM antibodies and their potential implication in immunity to SARS-CoV-2.
Methods: We performed a longitudinal study to quantify anti-S SARS-CoV-2 IgG and IgM (IgG-S and IgM-S) in health care worker (HCW) recipients of the BNT162b2 vaccine. Samples were collected before administration (T0), at the second dose (T1) and three weeks after T1 (T2). The cohort included 1584 immunologically naïve to SARS-CoV-2 (IN) and 289 with history of previous infection (PI).
Findings: IN showed three patterns of responses: (a) IgG positive/IgM negative (36.1%), (b) coordinated IgM-S/IgG-S responses appearing at T1 (37.4%) and (c) IgM appearing after IgG (26.3%). Coordinated IgM-S/IgG-S responses were associated with higher IgG titres. In IgM-S positive PI, 64.5% were IgM-S positive before vaccination, whereas 32% and 3.5% developed IgM-S after the first and second vaccine dose, respectively. IgM-S positive sera had higher pseudovirus neutralization titres compared to the IgM-S negative.
Interpretation: Coordinated expression of IgG-S and IgM-S after vaccination was associated with a significantly more efficient response in both antibody levels and virus-neutralizing activity. The unconventional IgG-S positive/IgM-S negative responses may suggest a recruitment of cross coronaviruses immunity by vaccination, warranting further investigation.
Funding: Italian Ministry of Health under "Fondi Ricerca Corrente"- L1P5 and "Progetto Ricerca Finalizzata COVID-2020-12371675"; FUR 2020 Department of Excellence 2018-2022, MIUR, Italy; The Brain Research Foundation Verona.

Keywords: BTN162b2 vaccine; COVID-19; IgG; IgM; SARS-CoV-2; Spike.
 
Back
Top Bottom